Improving gut health with human milk oligosaccharides

17 May 2019

2’-FL a very promising agent for digestive health across various age groups beyond infancy.

BASF and Glycosyn have signed a partnership agreement for the development and commercialization of human milk oligosaccharides (HMOs) for broad use in dietary supplements, functional nutrition, and medical food. The strategic partnership includes exclusive license of Glycosyn's patent portfolio for gut health beyond infant nutrition to BASF. The agreement aims to improve gastrointestinal health in adolescents and adults, along with broadening the applications of HMO for further health conditions.

Improving gut health with human milk oligosaccharides
Representatives from BASF and Glycosyn signed a collaboration agreement on May 14, 2019 endorsing their commitment to advance nutrition with novel HMOs.

As part of the collaboration and under the exclusive license, BASF will extend its offering of the most abundant HMO, 2’-Fucosyllactose (2’-FL) branded Prebilac, to a broad range of customers worldwide. Glycosyn will leverage its scientific expertise and extensive collaboration with the HMO research community to expand the evidence for adult health.

Emerging scientific evidence shows that 2’-FL supports the development and maintenance of a healthy gut microbiome and immune system. Based on its prebiotic functions and the ability to inhibit pathogen adhesion and modulate immune functions, 2’-FL is a very promising agent for digestive health across various age groups beyond infancy.

“Extending the reach of nature-designed HMO molecules from infant nutrition to dietary supplements, functional nutrition, and medical food addresses unmet consumer health needs and unlocks a huge market potential. Partnering with Glycosyn, the pioneer in the field of HMOs, to establish synergies and advance the science on HMOs for human gut health and even beyond, creates significant value for us and profound benefits for consumers,” said Tina Low, Vice President, Business Management Human Nutrition at BASF.

“The time has come to bring the benefits of HMO to consumers worldwide who suffer from gut discomfort or even diseases such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). BASF’s scaled state-of-the-art production and extensive global customer access makes them the ideal partner for us to jointly tap into this huge market potential and take nutrition to the next level,” added John Garrett, co-CEO, Glycosyn.

Read More

Related news

HALIX starts operational production with new cGMP facility in Q4-2019

HALIX starts operational production with new cGMP facility in Q4-2019

15 Aug 2019

The five-level production facility contains a state-of-the-art manufacturing line for viral vaccines and viral vectors and a separate protein manufacturing area with a capacity up to 1,000-L single-use bioreactors.

Read more 
Delivering complete aseptic vial handling solutions

Delivering complete aseptic vial handling solutions

14 Aug 2019

Bringing freeze drying and vial washing/sterilizing technologies together with advanced and comprehensive vial and syringe filling capabilities.

Read more 
Hikma expands nasal spray capabilities

Hikma expands nasal spray capabilities

12 Aug 2019

Company acquires unit-dose nasal and sublingual spray manufacturing equipment, as well as two pipeline products.

Read more 
How real-world data can revolutionise drug development

How real-world data can revolutionise drug development

9 Aug 2019

Utilising the current data environment and its data pools for the benefit of advancing research.

Read more 
Sartorius launches new services for mammalian cell bank manufacturing

Sartorius launches new services for mammalian cell bank manufacturing

8 Aug 2019

Integrated package of new and established services saves time and minimizes risks.

Read more 
Using mobile phones to fight Alzheimer’s disease

Using mobile phones to fight Alzheimer’s disease

8 Aug 2019

Researchers study how radiofrequency electromagnetic fields could be used in Alzheimer’s disease therapy.

Read more 
Cambrex to be acquired by the Permira funds

Cambrex to be acquired by the Permira funds

7 Aug 2019

The CDMO's shareholders will receive $60.00 per share in cash.

Read more 
Automation-compatible prepared culture media plate technology

Automation-compatible prepared culture media plate technology

6 Aug 2019

Thermo Fisher Scientific's SmartPlate format brings together Oxoid and Remel prepared culture media with a durable, universal plate design, helping customers to deliver accurate results across both automated and manual methods.

Read more 
Colorcon to incorporate TruTag's edible 'optical barcodes' in tablet film coatings

Colorcon to incorporate TruTag's edible 'optical barcodes' in tablet film coatings

6 Aug 2019

The benefits of this innovation include the ability to instantly and unequivocally authenticate products when suspect events.

Read more 
Growing domestic manufacturing creates new opportunities for international pharma in the Middle East

Growing domestic manufacturing creates new opportunities for international pharma in the Middle East

5 Aug 2019

Opportunities abound at CPhI MEA and experts anticipate regional generic companies acting as CMOs for international companies looking to enter the region.

Read more